Articles related to ANTIDEPRESSANTS

This meta analysis of antidepressants in MDD included 34 double-blind, randomized, placebo-controlled studies covering 20 antidepressants. Outcomes were 6-month relapse rates and tolerability measures. Fourteen of the agents had better relapse rates than placebo. Four — desvenlafaxine, paroxetine, venlafaxine, and vortioxetine — displayed the best efficacy and tolerability.

Pregnant women who filled prescriptions for bupropion, citalopram, escitalopram, fluoxetine, or sertraline during pregnancy (antidepressant-exposed cohort) and pregnant women who did not fill an antidepressant prescription within 90 days of the start of their pregnancy through delivery (control group) were the subjects of the study conducted by researchers from Brigham and Women’s Hospital in the United States. The main finding concerned the frequency of ADHD, autism spectrum disorder (ASD), behavioral disorder, developmental coordination disorder, developmental speech or language disorder, intellectual disability, any NDDs, and specific learning disorders among the children of the women in the study.

Some studies in children have reported a relationship between antidepressant use in pregnancy and neurodevelopment disorders after birth. In this analysis of 145,702 antidepressant-exposed and 3,032,745 unexposed pregnancies, crude results suggested up to a doubling in risk of neurodevelopmental outcomes. Significantly, however, no association was observed after balancing for confounding variables.

Data on more than 200,000 individuals revealed that non-SSRI antidepressants were associated with a two-fold increased risk of coronary heart disease, cardiovascular mortality, and all-cause mortality at ten years. There was also evidence that SSRIs were associated with lower rates of hypertension and diabetes.

Patients discontinuing antidepressant therapy experience insomnia, flu-like symptoms, mood disturbances, dizziness, and paresthesias — among a broad array of adverse effects. Those symptoms can last for days to months. This narrative review describes the array of discontinuation symptoms and their causes and provides practical clinical guidance for discontinuing antidepressants to minimize the risk of antidepressant discontinuation syndrome (ADS).

Study: This meta-analysis includes 232 randomized, double-blind, placebo-controlled trials of drug monotherapy for major depressive disorder submitted to the FDA between 1979 and 2016, and comprises nearly 75,000 adult and child participants. Conclusion: Patients with depression are likely to improve substantially from acute treatment of their depression with drug or placebo. Although the mean effect of antidepressants is only a small improvement over placebo, the effect of active drug seems to increase the probability that any patient will benefit substantially from treatment by about 15%.